Neurology, Vol 45, Issue 6 1122-1126, Copyright © 1995 by American Academy of Neurology

ARTICLES

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age

LA Stone, ME Smith, PS Albert, CN Bash, H Maloni, JA Frank and HF McFarland
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

MRI has provided insight into the pathophysiology and course of MS, particularly through the use of a paramagnetic contrast agent that allows visualization of blood-brain barrier (BBB) breakdown. Neither the overall frequency of BBB breakdown in MS patients nor the characteristics associated with BBB breakdown in MS are known. We studied 68 relapsing-remitting MS (RRMS) patients with three monthly MRIs to examine these questions. Seventy-eight percent of the RRMS patients studied had evidence of BBB breakdown on at least one MRI. While there was a great deal of variability among patients in terms of mean enhancing lesion frequency, BBB breakdown was associated with younger age at onset of disease, measured by age at first symptom or age at diagnosis, and more severe disease as measured by Expanded Disability Status Scale scores equal to or greater than 4.0. We found no relationship between BBB breakdown and duration of disease or gender. We conclude that BBB breakdown is a relatively common phenomenon in RRMS patients and may be most commonly found in patients with more aggressive disease and younger onset. These findings have implications for clinical trials that use MRI as an outcome measure.

This article has been cited by other articles:

				W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, A J Thompson, and D H Miller Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study Multiple Sclerosis, March 1, 2007; 13(2): 178 - 185. [Abstract] [PDF]

				A. T. Argaw, Y. Zhang, B. J. Snyder, M.-L. Zhao, N. Kopp, S. C. Lee, C. S. Raine, C. F. Brosnan, and G. R. John IL-1beta Regulates Blood-Brain Barrier Permeability via Reactivation of the Hypoxia-Angiogenesis Program J. Immunol., October 15, 2006; 177(8): 5574 - 5584. [Abstract] [Full Text] [PDF]

				F. Barkhof, U. Held, J. H. Simon, M. Daumer, F. Fazekas, M. Filippi, J. A. Frank, L. Kappos, D. Li, S. Menzler, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials Neurology, November 8, 2005; 65(9): 1447 - 1454. [Abstract] [Full Text] [PDF]

				A. B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, H.F. McFarland, and J. A. Frank Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN{beta}-1b Neurology, September 10, 2002; 59(5): 688 - 694. [Abstract] [Full Text] [PDF]

				S Skurkovich, A Boiko, I Beliaeva, A Buglak, T Alekseeva, N Smirnova, O Kulakova, V Tchechonin, O Gurova, T Deomina, et al. Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 277 - 284. [Abstract] [PDF]

				G. L. Mancardi, R. Saccardi, M. Filippi, F. Gualandi, A. Murialdo, M. Inglese, M. G. Marrosu, G. Meucci, L. Massacesi, A. Lugaresi, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS Neurology, July 10, 2001; 57(1): 62 - 68. [Abstract] [Full Text] [PDF]

				M. A. A. van Walderveen, G. J. Lycklama a Nijeholt, H. J. Ader, P. J. H. Jongen, C. H. Polman, J. A. Castelijns, and F. Barkhof Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Imaging: Relation to Clinical Characteristics in Subgroups of Patients With Multiple Sclerosis Arch Neurol, January 1, 2001; 58(1): 76 - 81. [Abstract] [Full Text] [PDF]

				K. M. K. Boje and S. S. Lakhman Nitric Oxide Redox Species Exert Differential Permeability Effects on the Blood-Brain Barrier J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 545 - 550. [Abstract] [Full Text]

				G. P. A. Rice, M. Filippi, and G. Comi Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial Neurology, March 14, 2000; 54(5): 1145 - 1155. [Abstract] [Full Text] [PDF]

				F Bagnato, A Tancredi, N Richert, C Gasperini, S Bastianello, C Bash, H McFarland, C Pozzilli, and J A Frank Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study Multiple Sclerosis, February 1, 2000; 6(1): 43 - 49. [Abstract] [PDF]

				F. Barkhof MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) Multiple Sclerosis, August 1, 1999; 5(4): 283 - 286. [Abstract] [PDF]

				E. K. Jordan, H. I. McFarland, B. K. Lewis, N. Tresser, M. A. Gates, M. Johnson, M. Lenardo, L. A. Matis, H. F. McFarland, and J. A. Frank Serial MR Imaging of Experimental Autoimmune Encephalomyelitis Induced by Human White Matter or by Chimeric Myelin-Basic and Proteolipid Protein in the Common Marmoset AJNR Am. J. Neuroradiol., June 1, 1999; 20(6): 965 - 976. [Abstract] [Full Text]

				M. A. A. van Walderveen, L. Truyen, B. W. van Oosten, J. A. Castelijns, G. J. Lycklama a Nijeholt, J. H. T. M. van Waesberghe, C. Polman, and F. Barkhof Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis: Relation to Inflammatory Activity Arch Neurol, March 1, 1999; 56(3): 345 - 351. [Abstract] [Full Text] [PDF]

				N Tubridy, H J Ader, F Barkhof, A J Thompson, and D H Miller Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups J. Neurol. Neurosurg. Psychiatry, January 1, 1998; 64(1): 50 - 55. [Abstract] [Full Text]